Pembrolizumab Boosts OS for Triple-Negative Breast Cancer

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, early-stage triple-negative breast cancer. The findings, derived from the KEYSTONE-522 trial, strongly support using this pembrolizumab regimen as the standard-of-care therapy for this difficult-to-treat disease.